<DOC>
	<DOC>NCT01859923</DOC>
	<brief_summary>The purpose of this trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of long-term (6-month) treatment with delamanid plus an optimized background regimen of other anti-tuberculosis drugs in pediatric patients who completed Trial 242-12-232.</brief_summary>
	<brief_title>A 6-Month Safety, Efficacy, and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis</brief_title>
	<detailed_description>This is a phase 2, open-label, multiple-dose, multicenter trial to assess the safety, tolerability, pharmacokinetics, and efficacy of delamanid plus an optimized background regimen in pediatric patients with MDR-TB over a 6-month treatment period. This long-term trial, an extension of Trial 242-12-232, will be conducted in patients who have completed Trial 232. Enrollment is complete for patients in Groups 1, 2, and 3.</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
	<criteria>Successfully completed Trial 24212232 Confirmed diagnosis of MDRTB OR Presumptive diagnosis of pulmonary or extrapulmonary MDRTB including one of the following: Clinical specimen suggestive of tuberculosis disease Persistent cough lasting &gt; 2 weeks Fever, weight loss, and failure to thrive Findings on recent chest radiograph (prior to Visit 1) consistent with TB AND Household contact with a person with known MDRTB or with a person who died while appropriately taking drugs for sensitive TB OR On firstline TB treatment but with no clinical improvement Negative urine pregnancy test for female patients who have reached menarche Written informed consent/assent Patients who have not completed Trial 24212232 Laboratory evidence of active hepatitis B or C Children with body weight &lt; 5.5 kg For patients with HIV coinfection, CD4 cell count ≤ 1000/mm3 for children 15 years old, and ≤ 1500/mm3 for children less than 1 year old History of allergy to metronidazole and any disease or condition in which metronidazole is required Use of amiodarone within 12 months or use of other predefined antiarrhythmic medications within 30 days prior to first dose of delamanid Serious concomitant conditions Preexisting cardiac conditions Abnormalities in Screening ECG (including AV block, BBB or hemiblock, QRS prolongation &gt; 120 msec, or QTcF &gt; 450 msec in both males and females) Concomitant condition such as renal impairment characterized by serum creatinine levels &gt;1.5 mg/dL, hepatic impairment (ALT or AST &gt; 3x ULN), or hyperbilirubinemia characterized by total bilirubin &gt; 2x ULN Current diagnosis of severe malnutrition or kwashiorkor Positive urine drug screen (Groups 1 and 2 only) Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid and/or any prior or concurrent use of bedaquiline Lansky Play Performance Score &lt; 50 (not applicable for children &lt; 1 year old) or Karnofsky Score &lt; 50 Administered an IMP within 1 month prior to Visit 1 other than delamanid given as IMP in Trial 24212232 Pregnant, breastfeeding, or planning to conceive or father a child within the timeframe described in the informed consent form (Groups 1 and 2 only)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Tuberculosis, Multidrug-Resistant</keyword>
	<keyword>Mycobacterium Infections</keyword>
	<keyword>Actinomycetales Infections</keyword>
	<keyword>Gram-Positive Infections</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Pediatric</keyword>
</DOC>